(1)
PO13 | Monitoring of Anti-Factor XA Activity Levels in Patients Treated With Direct Oral Anticoagulants and Concomitant Tyrosine Kinase Inhibitors Agents: A Monocentric Experience: E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy. Bleeding Thromb Vascul Biol 2025, 4 (s1). https://doi.org/10.4081/btvb.2025.313.